Suppliers / Zhejiang Apeloa Tospo Pharmaceutical

Zhejiang Apeloa Tospo Pharmaceutical

China Updated 9 July 2026

Zhejiang Apeloa Tospo Pharmaceutical is an API manufacturer based in China. It holds 2 active US drug master files and one valid CEP across a filed portfolio of 2 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 24 October 2025 as NAI.

2
active US DMFs
1
valid CEPs
2
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
2 of 2 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 24 October 2025 NAI US FDA
  • 13 March 2014 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Dongyang City, China Not on file
China, China 3008259952

What they file, and where

Molecule Regulators Docs
Cefixime EDQM, US FDA 2
Cefdinir US FDA 1

Also appears on these molecule pages

Cefdinir API Cefixime API

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA None 1

Questions about Zhejiang Apeloa Tospo Pharmaceutical

Does Zhejiang Apeloa Tospo Pharmaceutical hold a US DMF or a CEP?
Zhejiang Apeloa Tospo Pharmaceutical holds 2 active US drug master files and 1 valid CEP. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Zhejiang Apeloa Tospo Pharmaceutical FDA-registered?
One site operated by Zhejiang Apeloa Tospo Pharmaceutical carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Zhejiang Apeloa Tospo Pharmaceutical's last inspection go?
The most recent inspection on record closed on 24 October 2025 as NAI (No Action Indicated: nothing objectionable was found). 2 inspections are on file.
Where does Zhejiang Apeloa Tospo Pharmaceutical manufacture?
2 registered sites are on record, in China (Dongyang City and China). Every site is listed on this page with the register it came from.
What does Zhejiang Apeloa Tospo Pharmaceutical make?
2 molecules are on record against Zhejiang Apeloa Tospo Pharmaceutical, including Cefixime and Cefdinir. Each links through to that molecule's full manufacturer list.
Which regulators recognise Zhejiang Apeloa Tospo Pharmaceutical's GMP?
Current GMP certificates are on record from US FDA. GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Zhejiang Apeloa Tospo Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 24 October 2025.

Comparable suppliers

Apitoria Pharma shares 2 molecules Lupin shares 2 molecules Orchid Pharma shares 2 molecules Sandoz shares 2 molecules Nectar Lifesciences shares 2 molecules

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates